These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17258656)

  • 21. Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes.
    Munro NM; Levy JC
    Prim Care Diabetes; 2007 Jun; 1(2):103-5. PubMed ID: 18632028
    [No Abstract]   [Full Text] [Related]  

  • 22. DPPIV inhibition: promising therapy for the treatment of type 2 diabetes.
    Wiedeman PE
    Prog Med Chem; 2007; 45():63-109. PubMed ID: 17280902
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of gut hormones in glucose homeostasis.
    Drucker DJ
    J Clin Invest; 2007 Jan; 117(1):24-32. PubMed ID: 17200703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sitagliptin.
    Lyseng-Williamson KA
    Drugs; 2007; 67(4):587-97. PubMed ID: 17352516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.
    Vella A; Bock G; Giesler PD; Burton DB; Serra DB; Saylan ML; Dunning BE; Foley JE; Rizza RA; Camilleri M
    Diabetes; 2007 May; 56(5):1475-80. PubMed ID: 17303799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
    Drucker DJ
    Diabetes Care; 2007 Jun; 30(6):1335-43. PubMed ID: 17337495
    [No Abstract]   [Full Text] [Related]  

  • 28. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
    Juillerat-Jeanneret L
    J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
    Ahrén B
    Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
    [No Abstract]   [Full Text] [Related]  

  • 30. DPP-4 inhibitors in the treatment of type 2 diabetes.
    Duez H; Cariou B; Staels B
    Biochem Pharmacol; 2012 Apr; 83(7):823-32. PubMed ID: 22172989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.
    Ahmed HA; May DW; Fagan SC; Segar L
    Pharmacotherapy; 2015 Mar; 35(3):277-97. PubMed ID: 25754657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut hormones and related concepts.
    Bloomgarden ZT
    Diabetes Care; 2006 Oct; 29(10):2319-24. PubMed ID: 17003315
    [No Abstract]   [Full Text] [Related]  

  • 34. Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α
    van Baar MJB; van Raalte DH; Muskiet MHA
    Diabetes Care; 2017 Nov; 40(11):e157-e158. PubMed ID: 29061589
    [No Abstract]   [Full Text] [Related]  

  • 35. Response to Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α
    Lovshin JA; Lovblom LE; Cherney DZI
    Diabetes Care; 2017 Nov; 40(11):e159-e160. PubMed ID: 29061590
    [No Abstract]   [Full Text] [Related]  

  • 36. New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors.
    Hulin B; Cabral S; Lopaze MG; Van Volkenburg MA; Andrews KM; Parker JC
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4770-3. PubMed ID: 16115768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of the biological activity of chemokines by dipeptidyl peptidase IV--a side effect in the use of inhibitors?
    Mentlein R; Schiemann F; Ludwig A; Brandt E
    Adv Exp Med Biol; 2003; 524():37-47. PubMed ID: 12675221
    [No Abstract]   [Full Text] [Related]  

  • 39. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
    McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
    Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.